Study or Subgroup	Cases, No.	Patients, No.	Response rate (95% CI)
Plasmacell disorders			
Aleman 2021	27	44	0.61 [0.47; 0.76]
Avivi 2021	133	171	0.78 [0.72; 0.84]
Bitoun 2021	24	27	0.89 [0.77; 1.00]
Chan 2021	142	161	0.88 [0.83; 0.93]
Chiarucci 2021	21	22	0.95 [0.87; 1.00]
Ehmsen 2021	82	103	0.80 [0.72; 0.87]
Figueriedo 2021	43	55	0.78 [0.67; 0.89]
Greenberger 2021	204	213	0.96 [0.93; 0.98]
Lockmer 2021	0	10	0.00 [0.00; 0.00]
Marasco 2021	49	52	0.94 [0.88; 1.00]
Marchesi 2021	40	50	0.80 [0.69; 0.91]
Rahav 2021	149	187	0.80 [0.74; 0.85]
Ramasamy 2021	198	214	0.93 [0.89; 0.96]
Schiller 2021	124	171	0.73 [0.66; 0.79]
Stampfer 2021	50	103	0.49 [0.39; 0.58]
Tzarfati 2021	40	53	0.75 [0.64; 0.87]
Heterogeneity: $Tau^2 = 0.7834$; $Chi^2 = 137.86$, df = 15 (P < 0.01); $I^2 = 89\%$			
Lymphoma			
Benjamini 2021	160	373	0.43 [0.38; 0.48]
Bergmann 2021	50	79	0.63 [0.53; 0.74]
Chiarucci 2021	12	16	0.75 [0.54; 0.96]
Crombie 2021	9	21	0.43 [0.22; 0.64]
Ehmsen 2021	133	222	0.60 [0.53; 0.66]
Figueriedo 2021	6	8	0.75 [0.45; 1.00]
Ghady 2021	10	19	0.53 [0.30; 0.75]
Ghione 2021	36	86	0.42 [0.31; 0.52]
Greenberger 2021	758	1091	0.69 [0.67; 0.72]
Jurgens 2021	41	67	0.61 [0.50; 0.73]
Lim 2021	19	22	0.86 [0.72; 1.00]
Marasco 2021	53	100	0.53 [0.43; 0.63]
Marchesi 2021	16	70	0.23 [0.13; 0.33]
Molica 2021	41	70	0.59 [0.47; 0.70]
Perry 2021	76	149	0.51 [0.43; 0.59]
Rahav 2021	96	188	0.51 [0.44; 0.58]
Shem-Tov 2021	23	32	0.72 [0.56; 0.87]
Shen 2021	107	181	0.59 [0.52; 0.66]
Sherman 2021	1	1	1.00 [1.00; 1.00]
Tadmor 2021	49	84	0.58 [0.48; 0.69]
Tamari 2021	11	14	0.79 [0.57; 1.00]
Tzarfati 2021	91	141	0.65 [0.57; 0.72]
Heterogeneity: $Tau^2 = 0.2212$; $Chi^2 = 155.99$, df = 21 (P < 0.01); $I^2 = 87\%$			
CLL			
Benjamini 2021	160	373	0.43 [0.38; 0.48]
Bergmann 2021	50	79	0.63 [0.53; 0.74]
Ehmsen 2021	66	121	0.55 [0.46; 0.63]
Ghady 2021	10	19	0.53 [0.30; 0.75]
Greenberger 2021	417	650	0.64 [0.60; 0.68]
Jurgens 2021	12	21	0.57 [0.36; 0.78]
Marasco 2021	11	21	0.52 [0.31; 0.74]
Molica 2021	41	70	0.59 [0.47; 0.70]
Shem-Tov 2021	2	2	1.00 [1.00; 1.00]
Shen 2021	88	160	0.55 [0.47; 0.63]
Tadmor 2021	49	84	0.58 [0.48; 0.69]
Tamari 2021	7	8	0.88 [0.65; 1.00]
Tzarfati 2021	16	34	0.47 [0.30; 0.64]
Heterogeneity: $Tau^2 = 0.0682$; $Chi^2 = 49.52$, df = 12 (P < 0.01); $I^2 = 76\%$			
Myeloproliferative diseases			
Cattaneo 2021	48	62	0.77 [0.67; 0.88]
Greenberger 2021	33	34	0.97 [0.91; 1.00]
Kozak 2021	71	74	0.96 [0.91; 1.00]
Marchesi 2021	56	62	0.90 [0.83; 0.98]
Shem-Tov 2021	11	16	0.69 [0.46; 0.91]
Tzarfati 2021	77	90	0.86 [0.78; 0.93]
Heterogeneity: $Tau^2 = 0.5587$; $Chi^2 = 16.08$, df = 5 (P < 0.01); $I^2 = 69\%$			
Agressive lymphoma			
Chiarucci 2021	2	2	1.00 [1.00; 1.00]
Crombie 2021	1	1	1.00 [1.00; 1.00]
Ehmsen 2021	29	34	0.85 [0.73; 0.97]
Ghione 2021	36	86	0.42 [0.31; 0.52]
Greenberger 2021	122	137	0.89 [0.84; 0.94]
Jurgens 2021	28	46	0.61 [0.47; 0.75]
Lim 2021	19	22	0.86 [0.72; 1.00]
Marasco 2021	53	100	0.53 [0.43; 0.63]
Perry 2021	34	69	0.49 [0.37; 0.61]
Shem-Tov 2021	3	6	0.50 [0.10; 0.90]
Sherman 2021	1	1	1.00 [1.00; 1.00]
Tamari 2021	4	6	0.67 [0.29; 1.00]
Tzarfati 2021	51	67	0.76 [0.66; 0.86]
Heterogeneity: $Tau^2 = 0.6238$; $Chi^2 = 74.75$, df = 12 (P < 0.01); $I^2 = 84\%$			
Acute leukemia			
Chiarucci 2021	5	11	0.45 [0.16; 0.75]
Greenberger 2021	46	51	0.90 [0.82; 0.98]
Shem-Tov 2021	65	80	0.81 [0.73; 0.90]
Sherman 2021	5	9	0.56 [0.23; 0.88]
Tamari 2021	69	75	0.92 [0.86; 0.98]
Tzarfati 2021	12	15	0.80 [0.60; 1.00]
Yeshurun 2021	68	76	0.89 [0.83; 0.96]
Heterogeneity: $Tau^2 = 0.6624$; $Chi^2 = 20.9$, df = 6 (P < 0.01); $I^2 = 71\%$